Klotz L - Search Results

1

Canadian Consensus Conference: The FDA decision on the use of 5ARIs.

Klotz L, Chetner M, Chin J, Finelli T, Fleshner N, Fradet Y, Goldenberg L, Nickel JC, Siemens R, So A, Sugar L, Zlotta A, Klein E, Parnes H, Penson D. Klotz L, et al. Can Urol Assoc J. 2012 Apr;6(2):83-8. doi: 10.5489/cuaj.12058. Can Urol Assoc J. 2012. PMID: 22511412 Free PMC article. No abstract available.

2

Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group.

Goldenberg SL, Klotz LH, Srigley J, Jewett MA, Mador D, Fradet Y, Barkin J, Chin J, Paquin JM, Bullock MJ, Laplante S. Goldenberg SL, et al. Among authors: klotz lh. J Urol. 1996 Sep;156(3):873-7. J Urol. 1996. PMID: 8709351 Clinical Trial.

3

A phase 1-2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma.

Klotz L, McNeill I, Fleshner N. Klotz L, et al. J Urol. 1999 Jan;161(1):169-72. J Urol. 1999. PMID: 10037391 Clinical Trial.

4

CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group.

Klotz LH, Goldenberg SL, Jewett M, Barkin J, Chetner M, Fradet Y, Chin J, Laplante S. Klotz LH, et al. Urology. 1999 Apr;53(4):757-63. doi: 10.1016/s0090-4295(98)00616-5. Urology. 1999. PMID: 10197852 Clinical Trial.

5

Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis.

Nam RK, Fleshner N, Rakovitch E, Klotz L, Trachtenberg J, Choo R, Morton G, Danjoux C. Nam RK, et al. Among authors: klotz l. J Urol. 1999 May;161(5):1521-4. J Urol. 1999. PMID: 10210387

6

Diet, androgens, oxidative stress and prostate cancer susceptibility.

Fleshner NE, Klotz LH. Fleshner NE, et al. Among authors: klotz lh. Cancer Metastasis Rev. 1998-1999;17(4):325-30. doi: 10.1023/a:1006118628183. Cancer Metastasis Rev. 1998. PMID: 10453275 Review.

7

Differences between urologists in the United States and Canada in the approach to prostate cancer.

Fleshner N, Rakovitch E, Klotz L. Fleshner N, et al. Among authors: klotz l. J Urol. 2000 May;163(5):1461-6. J Urol. 2000. PMID: 10751858

8

p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder.

Fleshner N, Kapusta L, Ezer D, Herschorn S, Klotz L. Fleshner N, et al. Among authors: klotz l. J Urol. 2000 Oct;164(4):1177-82. J Urol. 2000. PMID: 10992361

9

A randomized phase 3 study of intraoperative cavernous nerve stimulation with penile tumescence monitoring to improve nerve sparing during radical prostatectomy.

Klotz L, Heaton J, Jewett M, Chin J, Fleshner N, Goldenberg L, Gleave M. Klotz L, et al. J Urol. 2000 Nov;164(5):1573-8. J Urol. 2000. PMID: 11025707 Clinical Trial.

10

Early experience in intermediate-risk penile cancer with sentinel node identification using the gamma probe.

Akduman B, Fleshner NE, Ehrlich L, Klotz L. Akduman B, et al. Among authors: klotz l. Urology. 2001 Jul;58(1):65-8. doi: 10.1016/s0090-4295(01)01087-1. Urology. 2001. PMID: 11445481 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,085 results

Search Page

Filters